Researchers make progress understanding a rare pediatric cancer

National and International Presentations


Trippett T, Kuttesch J, Herzog C, Boklan J, Bagatell R, Hunger S, Arceci R, Lu H, Langer C, and Gore L. A Phase I study of cetuximab and irinotecan in pediatric patients (pts) with refractory solid tumors. Abstract # 9547. Presented at the American Society of Clinical Oncology Annual Meeting 2007.

Gore L, Kuttesch J, Hunger S, Herzog C, Narenderan A, Boklan J, Foreman N, Ivy S, Boucher N, and Trippett T. A Phase IB study of oxaliplatin in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Abstract # 9548. Presented at the American Society of Clinical Oncology Annual Meeting 2007.

Narenderan A, Gore L, Bagatell R, Whitlock J, Kersey J, Boklan J, Katzenstein H, Hunger S, Amid A, Booth K, Herzog C, Arceci R, Trippett T. An experimental model for target modulation analysis in early clinical trials: Effects on Hsp90 client proteins in cells of patients treated with 17-AAG. Abstract# 754608. Presented at the Pediatric Academic Societies' Annual Meeting 2007.

Poster Presentations

Bagatell R, Gore L, Egorin M, Ho R, Boucher N, Heller G, and Trippett T. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of 17-Allylamino-17-demethoxygeldanamycin (AAG) in children with solid tumors. Abstract# 9022. American Society of Clinical Oncology 2006 meeting.

Gore L, Kuttesch J, Herzog C, Bagatell R, Boklan J, Arceci R, Katzenstein H, Whitlock J, Deshpande R, Lu H, Weber M, Trippett T. 2008. A Phase I study of cetuximab and irinotecan in pediatric patients with refractory central nervous system tumors: a report from the Pediatric Oncology Experimental Therapeutics Investigators Consortium (POETIC). Oral Presentation at the 13th International Symposium on Pediatric Neuro-Oncology. June 2008.

Gore L, Trippett TM, Katzenstein H, Boklan J, Narendaren A, Smith A, Macy M, Narashimhan N, Turner C, Nieder M. 2010. A multi-center, first-in-pediatrics Phase I study of ridaforolimus (AP23573, MK-8669) in patients (pts) with refractory solid tumors. 2010. Presented at the Scientific Program, Poster Discussion, American Society of Clinical Oncology Annual Meeting. June 2010.

High Impact Publications

Cancer Metastasis - Biologic Basis and Therapeutics - By David Lyden, Danny R. Welch and Bethan Psaila. Cambridge University Press, April 2011

Farrar JE, Vlachos A, Atsidaftos E, Carlson-Donohoe H, Markello TC, Arceci RJ, Ellis SR, Lipton JM, Bodine DM. Ribosomal protein gene deletions in Diamond-Blackfan anemia. Blood. 2011 Dec 22;118(26):6943-51.

Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011 Feb 10;29(5):551-65.

Gore L, Rivera E, Basche M, Moulder-Thompson SL, Li J, Eppers S, Grolnic S, O'Bryant C, Cleere D, Elsayed YA, Eckhardt SG. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Invest New Drugs. 2011 Sep 20. [Epub ahead of print]

Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs. 2011 Oct;20(10):1455-67. Epub 2011 Sep 2.

Bagatell R, Herzog CE, Trippett TM, Grippo JF, Cirrincione-Dall G, Fox E, Macy M, Bish J, Whitcomb P, Aikin A, Wright G, Yurasov S, Balis FM, Gore L. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res. 2011 Feb 1;17(3):611-9. Epub 2010 Dec 2.

Chaponis D, Barnes JW, Dellagatta JL, Kesari S, Fast E, Sauvageot C, Panagrahy D, Greene ER, Ramakrishna N, Wen PY, Kung AL, Stiles C, Kieran MW. Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. J Neurooncol. 2011 Aug;104(1):179-89.

Grill J, Puget S, Andreiuolo F, Philippe C, Macconaill L, Kieran MW. Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer. 2011 Dec 20. doi: 10.1002/pbc.24060. [Epub ahead of print]

Neville KA, Becker ML, Goldman JL, Kearns GL. Developmental pharmacogenomics. Paediatr Anaesth. 2011 Mar;21(3):255-65.

Jayanthan A, Bernoux D, Bose P, Riabowol K, Narendran A. Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition. Cancer Cell Int. 2011 Dec 29;11(1):44.

Baderali U, Jayanthan A, Hoeksma K, Narendran A,Giles W. W. Ion channels in pediatric CNS Atypical Teratoid/Rhabdoid Tumor (AT/RT) cells: potential targets for novel therapeutic agents. J Neurooncol. 2011 Oct 5. [Epub ahead of print]

Hoeksema KA, Jayanthan A, Cooper T, Gore L, Trippett T, Boklan J, Arceci RJ, Narendran A. Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia. Onco Targets Ther. 2011;4:149-68. Epub 2011 Sep 5.

Jayanthan A, Incoronato A, Blackmore C, Bernoux D, Lewis VA, Stam R, Whitlock JA and A. Narendran, Cytotoxicity, Combinability and Biological Correlates of ABT-737 Against Leukemia Cells with MLL Rearrangement. Pediatr Blood Cancer. 2011 Mar;56(3):353-60.

Bhagia P, Colanta AB, Abramson DH, Carlson DL, Kleinerman RA, Kraus D, Dunkel IJ. Sinonasal adenocarcinoma: a rare second malignancy in long term retinoblastoma survivors. Pediatr Blood Cancer. 2011 Oct;57(4):693-5.

Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of MicroRNA expression in pediatric brain tumors. Pediatr Blood Cancer. 2011 Feb;56(2):211-6.

Birks DK, Donson AM, Patel PR, Dunham C, Muscat A, Algar EM, Ashley DM, Kleinschmidt-Demasters BK, Vibhakar R, Handler MH, Foreman NK. High expression of BMP pathway genes distinguishes a subset of atypical teratoid/rhabdoid tumors associated with shorter survival. Neuro Oncol. 2011 Dec;13(12):1296-307

Bagatell R, Gore L, Egorin M, Ho R, Heller R, Boucher N, Zuhowski E, Whitlock J, Hunger S, Narendran A, Katzenstein H, Arceci R, Boklan J, Herzog C, Whitesell L Ivy S, and Trippett T. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics consortium study. Clin Cancer Research 2007; 13(6): 1783-1788.

Jayanthan A, Fowler J, Hawkins L, Lamers F, Teja B, Incoronato A, Anderson R and Narendran A. Effects of Hsp90 inhibition in neuroblastoma: Analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. J Novel Therap Oncol 2008; 7(3):183-93.

Narendran A, Coppes L, Jayanthan A, Coppes M, Teja B, Bernoux D, George D, and Strother D. Establishment of atypical-teratoid /rhabdoid tumor (ATRT) cell cultures from disseminated CSF cells: A model to elucidate biology and potential targeted therapeutics. J Neurooncol 2008; 90(2):171-80.

Jayanthan A, Howard S, Trippett T, Horton T, Daisley L, Lewis V, Whitlock J, Narendran A. Targeting the Bcl-2 family of proteins in Hodgkin Lymphoma: In vitro cytotoxicity, target modulation and drug combination studies of the BH3 mimetic ABT-737. Leukemia and Lymphoma 2009; 50(7):1174-82.

Trippett T, Herzog C, Whitlock J, Wolff J, Kuttesch K, Bagatell R, Hunger S, Boklan J, Smith A, Arceci R, Katzenstein H, Harbison C, Zhou X, Lu H, Langer C, Weber M, and Gore L. Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium (POETIC). J Clin Oncol 2009; 27(30):5102-8.

Contact Us | Privacy Policy | Terms & Conditions | Members | Board Powered by EmergingMed